OP0305 Disease interception in psoriasis patients with subclinical joint inflammation by interleukin 17 inhibition with secukinumab – data from a prospective open label study

Abstract

BackgroundMusculoskeletal changes precede the onset of psoriatic arthritis (PsA). A subset of psoriasis patients is characterised by arthralgia as well as inflammatory changes in the joints visible by MRI assessment. These patients have a high risk to progress into PsA.ObjectivesTo test the concept of a very early intervention in PsA we exposed psoriasis patients with subclinical joint inflammation to the anti-interleukin (IL)−17A antibody secukinumab. We hypothesised that IL-17A inhibition disrupted the early link between skin and joint disease in psoriasis.MethodsPsoriasis (but not PsA) patients were included in the open prospective 24 weeks ‘Interception in Very Early PSA’ (IVEPSA) study. To fulfil the inclusion criteria patients had to have a PASI score greater than 6 or nail or scalp involvement as well as inflammatory or erosive changes in MRI or high-resolution peripheral quantitative computed tomography (HRpQCT) at baseline. Patients received treatment with secukinumab 300 mg sc. for 24 weeks. MRI scans and HRpQCT of the dominant hand were performed at baseline and at 24 weeks. MRI was scored according to PsAMRIS. HRpQCT evaluated for erosions and enthesiophytes.Results20 patients (median age 49.5 years (IQR 42.8, 59), 70% males) with a median disease duration of 14 years (IQR 5, 20), were included into the study. At baseline, 85% reported arthralgia assessed by a Visual Analogue Scale (VAS) and 40% had tender joints on examination (TJC78). 83.3% had at least one inflammatory lesion in the MRI, 66.7% synovitis, 55.6% tendinitis/enthesitis, 27.8% osteitis and 16.7% periarticular inflammation. Erosions were present in 72.2% and 58.8% in the MRI and HRpQCT, respectively, while enthesiophytes were found in 33.3% and 41.2%. One patient was discontinued early due to lack of improvement (wk12) and one patient was unable to perform the follow-up MRI. Psoriatic skin disease (total PASI and BSA) significantly improved (both p<0.05) and also arthralgia (VAS pain, tender joint count) significantly declined after secukinumab treatment (both p<0.05). Total PsAMRIS score and synovitis subscore significantly improved at week 24 (p=0.005 and p=0.008, respectively). Importantly, improvement in total PsAMRIS score significantly correlated with the improvement in arthralgia (p<0.05). Finally, neither erosions nor enthesiophytes in MRI and HRpQCT progressed during the 24 weeks of treatment. There was no new safety signal in the study.ConclusionsIL-17 inhibition by secukinumab over 24 weeks led to resolution of inflammation and no progression of bone changes in the joints in psoriasis patients with subclinical peripheral joint involvement. These data suggest that very early disease interception in PsA is a feasible approach. IVEPSA also provides the guide for further very early interventions in PsA providing concepts for imaging-based identification and the sensitivity to change subclinical inflammation through biological disease modifying anti-rheumatic drug therapy.AcknowledgementsThis study was supported by an unrestricted g...

Regression of Peripheral Subclinical Enthesopathy in Therapy‐Naive Patients Treated With Ustekinumab for Moderate‐to‐Severe Chronic Plaque Psoriasis: A Fifty‐Two–Week, Prospective, Open‐Label Feasibility Study

“…To the best of our knowledge, this is the first study to evaluate the alteration in sonographic features of subclinical enthesitis with an IL‐12/IL‐23p40 inhibitor and the first study to investigate sonographic treatment responses in patients with asymptomatic psoriasis who are naive to systemic therapy. However, a recent study demonstrated that downstream inhibition of IL‐17 may have a similar effect on subclinical PsA ().…”

Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis

“…These results suggest that psoriasis patients who will develop PsA soon after diagnosis of psoriasis could be identified by unspecific arthritic symptoms and should therefore receive rheumatological care. Recent evidence suggests that early intervention treatment of PsA with biologic disease-modifying anti-rheumatic drugs (DMARDs) halts the progression of bone changes and decreases synovial inflammation [ 33 , 34 ].…”

A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis

“…The concept of disease interception was recently introduced (92). One hypothesis considers the possibility of arresting progression of psoriasis to PsA by targeting cytokines common to the pathogenesis of both diseases.…”

“…One recent cohort study found that systemic therapies for psoriasis may indeed reduce the incidence of PsA progression-especially the manifestation of dactylitis-compared with topical therapies among patients with psoriasis (93). In the Interception in Very Early PsA (IVEPSA) study, the anti-IL-17A antibody secukinumab arrested the progression of joint symptoms in patients with psoriasis, subclinical inflammatory changes, and arthralgia (92,94). Suppression of the IL-23/IL-17 axis with the IL-12/23 inhibitor ustekinumab reduced subclinical enthesopathy from 12 to !52 weeks of treatment in patients with moderate to severe psoriasis who had !1 entheseal change detected by ultrasonography and no diagnosis of PsA (95).…”